

8 May 2024

Botanix Webinar – Presentation Copy

Philadelphia PA and Perth Australia, 8 May 2024: Clinical dermatology company, Botanix Pharmaceuticals Limited (ASX: BOT, “Botanix” or “the Company”), announces that it will be hosting a webinar this morning - Wednesday, 8 May commencing at 10:30am AEST (Sydney/Melbourne) / 8:30am AWST (Perth) - to provide a comprehensive update on its commercial launch plans and market insights, as it nears planned approval of *Sofdra*TM.

A copy of the presentation that will be utilised during the call is attached with this release.

The call will be hosted by Executive Chairman, Vince Ippolito and Chief Executive Officer, Dr Howie McKibbon, along with key members of the newly expanded commercial team, including guest Lisa Pieretti, the Executive Director of the International Hyperhidrosis Society.

Interested participants need to register before the webinar using the link below and dial in details will be sent in return.

Webinar Details

Date: 8 May 2024

Time: 10:30am AEST (Sydney/Melbourne), 8:30am AWST (Perth)

To register: https://us02web.zoom.us/webinar/register/WN_mzSgKfFpQzyVLU16fe_SNw

Dial in details: Will be sent to you directly upon registration

Release authorised by

Vince Ippolito

President and Executive Chairman

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which is progressing its lead product *Sofdra* for the treatment of primary axillary hyperhidrosis through FDA approval. FDA accepted the resubmission of the NDA for *Sofdra* in January 2024 as a complete response and confirmed a target approval timing for late June 2024. *Sofdra* is positioned to be a leading first line and second line therapy and potentially represents a safe and effective new option for patients.

For personal use only

The Company also has a pipeline of other products in late-stage clinical development for range of other dermatology conditions. To learn more please visit: <http://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications
Botanix Pharmaceuticals
P: +61 8 6555 2945
investors@botanixpharma.com

Investor enquiries

Hannah Howlett
WE Communications
P: +61 450 648 064
hhowlett@we-worldwide.com

Media enquiries

Haley Chartres
H^CK
P: +61 423 139 163
haley@hck.digital

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

For personal use only

ersonal use only

Sofdra Commercial Plan

 **Sofdra**[™]
(sofipronium bromide) gel, 15%

Notice and Disclaimer

1. Summary information

This presentation has been prepared by Botanix Pharmaceuticals Ltd (“Botanix”) and contains summary information about Botanix and the business conducted by it which is current as at the date of this presentation (“Presentation”) (unless otherwise indicated).

The information in this Presentation is general in nature and does not purport to be accurate nor complete, nor does it contain all of the information that an investor may require in evaluating a possible investment in Botanix, nor does it contain all the information which would be required in a disclosure document or prospectus prepared in accordance with the requirements of the Corporations Act 2001 (Cth). It has been prepared by Botanix with due care but no representation or warranty, express or implied, is provided in relation to the accuracy, reliability, fairness or completeness of the information, opinions or conclusions in this Presentation by Botanix or any other party.

The information in this Presentation remains subject to change without notice. Reliance should not be placed on information or opinions contained in this Presentation, and Botanix does not have any obligation to finalize, correct or update the content of this Presentation. Certain data used in this Presentation has been obtained from research, surveys or studies conducted by third parties, including industry or general publications.

To the maximum extent permitted by law, Botanix is not responsible for updating, nor undertakes to update, this Presentation. It should be read in conjunction with Botanix’s other periodic and continuous disclosure announcements lodged with the ASX, which are available at www2.asx.com.au or at <https://botanixpharma.com/category/asx-releases/>.

2. Not an offer

Neither this Presentation nor any of its contents will form the basis of any understanding, proposal, offer, invitation, contract or commitment.

3. Industry data

Certain market and industry data used in connection with or referenced in this Presentation has been obtained from public filings, research, surveys or studies made or conducted by third parties, including as published in industry-specific or general publications. Neither Botanix nor its advisers, or their respective representatives, have independently verified any such market or industry data.

4. Financial data

All dollar values are in United States dollars (\$) or US\$) unless otherwise stated. Amounts, totals and change percentages are calculated on whole numbers and not the rounded amounts presented.

5. Forward-looking statements and forecasts

This Presentation contains certain “forward-looking statements” and comments about future matters. Forward-looking statements can generally be identified by the use of forward-looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions and include, but are not limited to, plans and prospects for the Company, the Company’s strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercializing product candidates or research collaborations with its partners, including in Japan, the outcome and effects of Sofpironium Bromide and the market for Sofpironium Bromide. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. You are cautioned not to place undue reliance on forward-looking statements. Any such statements, opinions and estimates in this Presentation speak only as of the date hereof, are preliminary views and are based on assumptions and contingencies subject to change without notice, as are statements about market and industry trends, projections, guidance and estimates. Forward-looking statements are provided as a general guide only. The forward-looking statements contained in this Presentation are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Botanix, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Any such forward looking statements are also based on assumptions and contingencies which are subject to change, and which may ultimately prove to be materially incorrect, as are statements about market and industry trends, which are based on interpretations of current market conditions. Investors should consider the forward-looking statements contained in this Presentation in light of those disclosures and not place undue reliance on such statements (particularly in light of the current economic climate and significant volatility, uncertainty and disruption caused by the COVID-19 pandemic). The forward-looking statements in this Presentation are not guarantees or predictions of future performance and may involve significant elements of subjective judgment, assumptions as to future events that may not be correct, known and unknown risks, uncertainties and other factors, many of which are outside the control of Botanix.

Except as required by law or regulation, Botanix undertakes no obligation to finalize, check, supplement, revise or update forward-looking statements or to publish prospective financial information in the future, regardless of whether new information, future events or results or other factors affect the information contained in this Presentation.

6. No liability

The information contained in this document has been prepared in good faith by Botanix. Neither Botanix, nor any of its advisers or any of their respective affiliates, related bodies corporate, directors, officers, partners, advisers, employees and agents have authorised, permitted or caused the issue, lodgment, submission, dispatch or provision of this Presentation in a final form and none of them makes or purports to make any binding statement in this Presentation and there is no statement in this Presentation which is based on any statement by them.

To the maximum extent permitted by law, Botanix and its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents: expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in this document including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any estimates or projections and any other financial information derived therefrom, whether by way of negligence or otherwise; and expressly exclude and disclaim all liabilities in respect of, make no representations regarding, any part of this Presentation and make no representation or warranty as to the currency, accuracy, adequacy, reliability or completeness or fairness of any statements, estimates, options, conclusions or other information contained in this Presentation.

Operations:

3602 Horizon Drive, Suite 160
King of Prussia PA 19406

Corporate Office:

Level 1, 50 Angove Street
North Perth W. Australia 6006

Authorized for release by:

Vince Ippolito
Executive Chairman

Botanix - accelerating towards commercialization of *Sofdra*TM

DERMATOLOGY FOCUS

New treatments for underserved common skin diseases, with a first focus on excessive sweating (“primary axillary hyperhidrosis”)

TOPICALLY DRIVEN

Targeting key indications with topical (gel) treatments that are safe, well tolerated and validated with clinical efficacy

WORLD CLASS TEAM

US-based team that have been responsible for successful development and commercial launches of more than 30 dermatology drugs

NEW PRODUCT “SOFDRA”

Sofdra is the first and only new chemical entity for primary axillary hyperhidrosis (5% product already approved in Japan with solid sales)

TARGETING MID-24 FDA APPROVAL

Submitted final component required for approval (the “Instructions for Use”) in Q1 CY2024, targeting FDA approval in June 2024



Corporate Overview

ASX: BOT TRADING INFORMATION

| | |
|------------------------------|----------------|
| Share price | A\$0.275 |
| 6-month low / high | A\$0.12/0.275 |
| Shares outstanding | 1,563,437,373 |
| Market Capitalization | A\$430m |
| Cash | A\$ 17.3m |
| Debt | Nil |

SUBSTANTIAL SHAREHOLDERS

| Shareholder | % |
|----------------------|------|
| Antares Capital | 9.0% |
| Board and Management | 7.0% |
| Top 20 | 33% |



Highly experienced board and management team

Developed, secured approval for, and commercialized over 30 successful dermatology products



VINCE IPPOLITO
Executive Chairman

- COO of Anacor and Medicis; former President of Dermavant more than 17 years at Novartis
- More than 35 years experience in pharma with 20+ years within dermatology



HOWIE MCKIBBON
Chief Executive Officer

- Former SVP Commercial of Dermavant, Anacor and Medicis
- 25+ years working in dermatology—launched more than 15 brands and managed over 35 dermatology products



DR PATRICIA WALKER
Chief Medical Adviser

- Former President and head of R&D Brickell Biotech
- Former CMO/CSO at Kythera, Inamed and Allergan Medical responsible for multiple products including Botox® and Tazorac®



MATT CALLAHAN
Board Executive Director

- Serial founder and ex-investment director of two venture capital firms in life sciences
- Founder Botanix, Churchill Pharma, Orthocell, Dimerix



DR BILL BOSCH
Board Director

- 30+ years experience in pharma industry
- Co-inventor of SoluMatrix™ drug delivery technology and NanoCrystal® Technology



JOHN SCHOHL
VP Managed Markets

- Former SVP Commercial Operations Medicis
- 30+ years experience in pharma industry with 23+ years within dermatology



DAVID MORGAN
Head of Corporate Affairs

- 20+ years as ad agency principal
- Clients included Intel, Citibank, and Qwest (CenturyLink)
- Vice President responsible for the Medicis in-house ad agency



DR JACK HOBLITZELL
SVP Pharmaceutical Development

- 30+ years leading world-class technical operations
- Senior leadership roles at Assertio Therapeutics, Pfizer, King, Ivax and Teva



DR BORIS MEYERSON
Chief Business Officer

- Launched four pharma companies
- 20+ years in dermatology
- Proven expertise in commercial operations

Experience across multiple therapeutic areas

EFFEXOR XR[®] EXTENDED
RELEASE
CAPSULES

SOLODYN[®]
(MINOCYCLINE HCl, USP)
EXTENDED RELEASE TABLETS

Aldara[®]
Imiquimod Cream 5% w/w

Carac[®]
fluorouracil cream

PROTONIX[®] 40 mg
(pantoprazole sodium)

ZIANA[®]
(clindamycin phosphate 1.2%
and tretinoin 0.025%) Gel

ELIDEL[®]
(pimecrolimus) cream 1%

eucrisa[®]
crisaborole ointment 2%

ALTACE[®]
(ramipril) capsules

TRIAZ[®]
(benzoyl peroxide)

Winlevi[®]
(clascoterone)
cream 1%

LOPROX[®]
(ciclopirox)

MetroGel-Vaginal[®]
(metronidazole vaginal gel)
0.75% Vaginal Gel

TREANDA

Zyclara[®]
(imiquimod) Cream
3.75%

Kerydin[®]
(TAVABOROLE)
TOPICAL SOLUTION, 5%

RETIN-A MICRO[®]
(tretinoin gel) microsphere, 0.1%

PROVIGIL[®]
(MODAFINIL) C
Tablets

Efudex-40[™]
(fluorouracil)

Vanos[®]
(fluocinonide) Cream, 0.1%

NUVIGIL[®]
(ARMODAFINIL) Tablets

 **Sofdra**[™]
(sofpironium bromide) gel, 15%


botanix
PHARMACEUTICALS

COMMERCIAL
DAY
2024

Patient Burden

ersonal use only

Patient Burden



International Hyperhidrosis Society



LISA J PIERETTI, MBA

Executive Director & Founding Member

- Previously Director of Account Management at Medical Broadcasting Company, where she designed, developed, and executed integrated multi-channel strategic marketing programs for billion-dollar pharma brands
- Worked with SCIREX Corporation, a leader in CNS clinical research, as the Senior Director of Marketing and Communications
- At Merck & Co. she was a Market Analyst in the vaccine department



Listen

The podcast for anyone living with a sweat disorder or concerned or curious about issues of human perspiration -- including excessive sweating or hyperhidrosis (Hh.)



Learn

Sign up and get news alerts about hyperhidrosis research postings, treatment discoveries, and important developments in the universe of sweating.




Watch

Watch videos of patient stories. Learn about Hyperhidrosis from top physicians treating this condition and see behind the scenes setup and treatment at our Master Class.

Top priorities include promoting awareness of hyperhidrosis, working to enable treatment access, and increased research into this medical condition

Hyperhidrosis: Significant unmet medical need

Clinicians ranked hyperhidrosis last in their ability to successfully manage with available treatments



Source: 1. Adapted from Cowen and Company analysis dated February 27, 2019; survey executed by ExpertConnect. **2.** 1 = most able to successfully manage; 6 = least able to successfully manage

 **Sofdra**TM
(sofipironium bromide) gel, 15%

botanix[®]
PHARMACEUTICALS


COMMERCIAL
DAY
2024

SofdraTM Overview

ersonal use only

Sofdra™ has a targeted mechanism of action

Binds selectively to M3 AC receptors, thereby blocking acetylcholine to inhibit sweat production, and then rapidly degrades for excretion



M3 AC Receptors = Muscarinic Acetylcholine Receptors which regulate the function of sweat glands

SB Metabolite = Sofpironium Bromide is converted into a less active form to help minimize side effects

Phase 3 pivotal program co-primary measures

Hyperhidrosis Disease Severity Measure-Axillary patient-reported outcome measure (HDSM-Ax)

- HDSM-Ax patient-reported outcome measure was used for a co-primary endpoint and all secondary endpoints
- HDSM-Ax is a validated patient-reported outcome measure of axillary hyperhidrosis severity
 - a 1-point change is clinically meaningful¹
- HDSM-Ax employs 7 questions on a 5-point scale
 - a similar children's version was used for children under age 12


Gravimetric Sweat Production (GSP) measure

- GSP was used for a co-primary endpoint and in composite secondary endpoints
- Prior to measurements subjects remained in a semi-recumbent position for at least 30 minutes in a room with controlled humidity and temperature between 20°C and 25°C
- GSP was performed by standard methods
- A separate 5-minute continuous GSP weight measurement was done for each axilla


- HDSM-Ax measured improvement from baseline to end of treatment (Week 6)
- GSP measured the change in sweat production from baseline to End of Treatment

Source 1. Hobart J, Burke L, Kirsch B, Chadha D. Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax): Evaluation of Measurement Performance. J Drugs Dermatol. 2021 Apr 1;20(4):410-418. doi: 10.36849/JDD.2021.5569.

In both Phase 3 studies, co-primary endpoints were observed to be highly statistically significant



HDSM-Ax scale measures patient reported severity of axillary (underarm) hyperhidrosis



GSP (Gravimetric Sweat Production) is an objective measurement of underarm sweat production (mg/ 5 min)

Baseline GSP: Vehicle 229.83 mg / SB Gel 15% 210.84 mg

Notes: 1. Data are based on multiple imputations for missing values; 'n' represents number of subjects in the ITT population; EOT = end of treatment

Sources: BBI-4000-CL-301; BBI-4000-CL-302

 **Sofdra**[™]
(sofpironium bromide) gel, 15%


 **botanix**
PHARMACEUTICALS

PERSONAL USE ONLY
COMMERCIAL
DAY
2024

Regulatory and manufacturing

PERSONAL USE ONLY


Instructions for Use revision - review being finalised with FDA



Instructions For Use

- ❖ Revised the Instructions For Use to further simplify the guidance for application ✓
- ❖ Updated bottle label and carton to prominently display “wash hands with soap and water immediately after use” ✓
- ❖ Conducted a *pilot* human factors study to demonstrate the revised Instructions For Use are reliably followed ✓
- ❖ Filed an end-of-review meeting request with FDA to be held end of November/start of December CY 2023 ✓
- ❖ Completed human factors *validation* studies to confirm revised Instructions for Use are reliably followed ✓
- ❖ Submitted to FDA and FDA communicated response was complete ✓


Manufacturing supplies and process settled



Proposed packaging subject to FDA approval

ersonal use only

Eversana – our 3rd Party Logistics provider (3PL)



Our 3PL partner can fulfill efficiently and cost-effectively:

- ❖ managing inventory (including DSCSA¹)
- ❖ order-to-cash process (receiving POs from our customers, picking, packing and shipping product, invoicing, and collecting payments on Botanix's behalf)
- ❖ customer service (through its call center)

Using a 3PL cuts down time to market from a year to a few weeks and does not require capital spend



¹ Drug Supply Chain Security Act, which is a federal law in the United States, enacted in 2013


COMMERCIAL
DAY
2024

Commercial Plan

 **Sofdra**TM
(sofpironium bromide) gel, 15%

ersonal use only

~3.7M patients are accessible by targeting derms and an additional 6.3M are accessible via digital



Source: 1. International Hyperhidrosis Society, 2. Dolittle, et al, 2016, Hyperhidrosis: an update on prevalence and severity in the United States, Archives of Dermatology Research
Confidential. Internal use only.

85% of patients and dermatologists would use and prescribe *Sofdra gel*¹

Significant opportunity exists for a new topical product to address unmet needs

“I can count on one hand my total armory for treating hyperhidrosis. I need more tools in my toolbox and a convenient product for my patients”



DERMATOLOGIST

UNMET NEED: ~6 OUT OF 7

“We are always looking for more efficacious therapies that are easier to take”



PAYER

UNMET NEED: ~4 OUT OF 7

A rating of 4 out of 7 is high based on our experience with payers across therapeutic areas

The treatments that we have are not very convenient and are pretty costly. I just feel like there are not enough options”



PATIENT

UNMET NEED: ~6 OUT OF 7

TOP 2
UNMET
NEEDS

- ① More efficacious treatments without access/cost concerns
- ② New treatment options (i.e., limited options)

Source: 1. Triangle Insights conducted interviews with US dermatologists (n=20), US payers (n=10), US patients (n=20) Q4 2022

Significant opportunity for a new topical agent with class leading efficacy and safety

No new chemical entities were ever approved for hyperhidrosis



Due to its significant psychological impact, 54% of respondents suffering from hyperhidrosis say that they would pay anything for a treatment to stop their excessive sweating¹

Source: 1. Doolittle, J. et al. Arch Dermatol Res, 2016.


Research indicates dermatologists would start new patients on *Sofdra* gel in addition to moving existing patients

CURRENT PRESCRIPTION PREFERENCES


PROSPECTIVE PRESCRIPTION PREFERENCES

FIRST LINE

Share of Patients Receiving Treatments (1L)




Share of Patients Receiving Treatments (1L)




SECOND LINE

Share of Patients Receiving Treatments (2L)



Share of Patients Receiving Treatments (2L)



*Share of patients by treatment type shows a weighted average across severities

Source: 1. Triangle Insights conducted interviews with US dermatologists (n=20), US payers (n=10), US patients (n=20)

Sofdra gel launch strategy

Rapidly establish *Sofdra* gel as a safe and effective first-line therapy for treatment of primary axillary hyperhidrosis



Engage and motivate

patients to take control of their hyperhidrosis and see a telemedicine doctor for diagnosis and prescription



Maximize reimbursement and coverage

through strategic contracting



Provide patient access and eliminate friction

to provide immediate fulfillment and automatic refills



Drive Derm adoption

via comprehensive engagement around a compelling clinical story



Hire and train a highly effective **Sales**

Force for immediate trial and adoption

 **Sofdra**[™]
(sofipronium bromide) gel, 15%


botanix
PHARMACEUTICALS

ersonal use only

COMMERCIAL
DAY
2024

Engage and Motivate Patients

Drive impact across the patient experience and validate across channels

Turning Data Into Insights



Pathmatics

SimilarWeb

reonate

iSpot.tv

snowflake


datorama
A Salesforce Company

tableau

botanix
PHARMACEUTICALS

ersonal use only

A data-centric approach allows us to activate our most valuable patient audiences cross-channel



Google and Microsoft Network



Data-Driven, Addressable TV/CTV/OTT





Efficient Scale



Premium Content

Social




Audio & Audio Display



Health Environments (Video/Display/Print)



Non-Health Environments (Video/Display)








Personal use only

AI content targeting tells us more about audiences who care and finds more like them

Social media as a cornerstone

HH Social Looks Different

-  **37k** highly active members on Reddit
-  **Significant** Twitch community
-  **191.4 million** lifetime views on hyperhidrosis-related TikToks
-  **Medium-sized closed FB groups**, with higher-than-average activity
-  **Lower than average** Instagram mentions and interaction

I didn't even realize a Dermatologist could treat this. I guess it makes sense because sweat comes from the skin.

- Chloe

[After Rx] I actually didn't fill it for months. I just was hoping it wasn't real.

- Sophie

After my diagnosis in college, I didn't even tell my family. I don't need them to know.


- Sabina

I guess I just stopped taking anything because it wasn't worth it. But honestly my sweat is still so bad. I'm probably going to have to get another soon – I wish something worked better.

- Patient

WHERE THEY ARE

of Gen Z



of Gen Z is using social to search for more info about brands BEFORE search engines

Hone in on actual patients during moments of sharing sweat stories with AI social sentiment targeting


Engage 396,464+ highly qualified hyperhidrosis patients per month while they are talking about their symptoms and personal journeys

1 SOCIAL POSTS/HASHTAGS



HASHTAG EXAMPLES:


- #hyperhidrosis
- #sweatyfeet
- #sweatfree
- #excessivesweating
- #sweatproblems
- #sweatissues



2 IMAGES/VIDEOS



3 AUDIO RECOGNITION



 **Sofdra**[™]
(sofipronium bromide) gel, 15%

 **botanix**
PHARMACEUTICALS

ersonal use only

COMMERCIAL
DAY
2024

Reimbursement and coverage

What is reimbursement?


- ❖ In 2022 in the US¹: 92.1% of people, or 304 million individuals had health insurance (65.6% private + 36.1% government²)
- ❖ Health insurance comes with a “medical benefit” that largely covers medical treatments³ and a “pharmacy benefit” that covers all, or a part of the cost of drugs
- ❖ *Sofdra*, as a self-administered drug, will be covered under the pharmacy benefit and does not require a “code” for coverage
- ❖ HH is a recognized medical condition with existing coverage policies
- ❖ Engaged in discussions with payers to provide patients with frictionless access not only for the first fill but every refill

¹ [Health Insurance Coverage in the United States: 2022 \(census.gov\)](#), accessed 2024-05-01

² These statistics are based on having each insurance type at least once in the year, therefore leading to a total over 100% because of patients switching insurance types

³ When a drug is administered in the office, HCPs claim medical reimbursement via J-codes to cover the cost of the drug and CPT codes to cover the cost of their labor

Sofdra reimbursement as a part of the overall process



¹ For commercial patients only

Key payer account prioritization and engagement timing

Execute contracts with contracting PBMs and downstream clients in 2 phases

| Phase 1 Accounts | | |
|------------------|--------------------|-------|
| | Zinc Health | 35.1M |
| | Caremark PCS | 2.1M |
| | Ascent Health | 22.6M |
| | Express Scripts | 1.2M |
| | Emisar Health | 27M |
| | OptumRx Government | 750k |
| | Kaiser | 8.1M |
| Emisar | United Healthcare | 12.6M |
| Zinc | Aetna Health | 6M |
| Ascent | Cigna | 9M |
| Zinc | Elevance (Anthem) | 6.1M |
| Ascent | Prime Therapeutics | 33.5M |

| Phase 2 Accounts | | | | | | |
|------------------|----------------------------------|------|--------|---------------------------|--|------|
| CVS | Federal Employees Health Benefit | 5.5M | Ascent | Premera | | 1.1M |
| Zinc | Wellmark | 950k | Ascent | Medical Mutual OH | | 560k |
| Zinc | CareFirst BCBS | 1M | Emisar | Independence BC | | 1M |
| Zinc | BCBS MA | 1.3M | Ascent | Emblem Health | | 400k |
| Zinc | Blue Shield CA | 1.8M | Ascent | Kroger PBM | | 700k |
| Emisar | BCBS SC | 400k | Emisar | BCBS AZ | | 380k |
| Ascent | HCSC Members | 5.5M | Ascent | BCBS MN | | 735k |
| Ascent | Horizon BCBS NJ | 500k | Ascent | BCBS KS | | 294k |
| Ascent | Florida Blue | 1.2M | Emisar | BCBS Kansas City | | 376k |
| Ascent | Regence / Cambia | 1.1M | Emisar | BCBS Michigan | | 170k |
| Ascent | BCBS NC | 730k | Ascent | Elixir PBM | | 850k |
| Ascent | BCBS AL | 1.2M | FLRx | Lifetime Healthcare | | 800k |
| Ascent | BCBS LA | 700k | -- | Procare/MC21 | | 560k |
| Ascent | HMSA Hawaii | 385k | -- | Dividend Group/ MedImpact | | 1M |
| Ascent | Humana Health | 600k | Ascent | BCBS Highmark | | 190k |

Key: Rx Contracting PBM Phase 1 Account Phase 2 Account Total Lives

SofdraTM
(sofpironium bromide) gel, 15%

botanix
PHARMACEUTICALS

ersonal use only


COMMERCIAL
DAY
2024

Frictionless Access with Telemedicine and Fulfillment



Telemedicine platforms are now a mainstream tool for many companies in a wide range of indications

Examples of Companies Partnering with Telemedicine Solutions



Pfizer: Nurtec ODT brand.com page, with link to the telehealth platform

Migraine



Psychiatry



Birth Control



Diabetes



Respiratory



Obesity



Gastroenterology




WWW.BOTANIXPHARMA.COM

Personal use only

Telehealth is essential for new product commercialization

and significantly speeds time to therapy, especially with clinical diagnoses like HH¹



¹ Clinical diagnoses are based on observation, interaction with the patient and medical knowledge. They do not require tests




GetSofdra.com telehealth site powered by UpScript Health

Patients can reach GetSofdra.com via link from Sofdra.com or by organic search

Patients are prompted to register and provide contact information up front to allow email follow-up with the patient

The medical questionnaire was designed to collect information required to address possible Sofdra PAs

After scheduling with an HCP, reminder emails are sent including links to the start page



 **Sofdra**[™]
(sofipironium bromide) gel, 15%

 **botanix**
PHARMACEUTICALS

ersonal use only

COMMERCIAL
DAY
2024

Drive Dermatology Adoption

Derm tactics are grounded in a compelling clinical story

Field Force will be armed with Data

Comprehensive tools will enable sales force to effectively convey the Sofdra gel story and provide opportunity for demonstration

- ✓ Quick & Clear Visuals
- ✓ Optimistic Tone
- ✓ A Touch of Humor

If you're drier and you show it, raise your hand!

Sara Sofdra patient
"That's me, confident in light gray and looking drier"

Sofdra
(sofopirium bromide) gel

If you have excessive underarm sweating (hyperhidrosis), how much drier could you be with Sofdra?

Sweat produced in about 11 hours and 40 minutes:

- 1 ounce
- Normal Sweating

At the beginning of the clinical trial
An average patient could fill this shot glass with sweat.

At the end of the clinical trial
60% of patients who achieved the trial's two main goals would fill the glass to here
In 1 hour these same patients would only sweat this much.

Get a prescription by phone. Call 844-SofdraRx
Pay as little as \$0

What is Sofdra?
Sofdra (sofopirium bromide) gel, 15%, is a prescription medication used on the skin to treat excessive underarm sweating (primary axillary hyperhidrosis) in people 9 years of age and older.

What is the most important information I should know about Sofdra?

Who should not use Sofdra?
Sofdra (sofopirium bromide) gel, 15%, is a prescription medication used on the skin to treat excessive underarm sweating (primary axillary hyperhidrosis) in people 9 years of age and older.

More

On one measure of the HD5M-Ax-7 scale, XX% of subjects improved from strongly to slightly "Feeling the need to change clothes because of your underarm sweating."

Sofdra is the first new molecular entity ever approved for primary axillary hyperhidrosis

>60% of Subjects had a ≥2 point Improvement in HD5M-Ax-7 from Baseline to EOT*

No Sweat 0 1 2 3 4 Worst Possible Sweating

Important Information
Sofdra (sofopirium bromide) gel, 15% is indicated for topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older. Treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older. Primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older. Treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older.

INDICATION AND USAGE
Sofdra (sofopirium bromide) gel, 15% is indicated for topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older.

IMPORTANT SAFETY INFORMATION
Proportion with ≥2 point improvement in HD5M-Ax-7 from Baseline to End of Treatment (EOT) in subjects with primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older. Primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older. Primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older. Primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older.

Apply 1 pump of Sofdra per underarm once a day at bedtime

Sofdra is supplied in a multi-dose metered pump, applicator, and cap. Each bottle is capable of dispensing 60 pump applications in 30-day supply.

How to Apply Sofdra
Apply once per day at bedtime. See Important Safety Information for more information.

Important Safety Information
Sofdra is flammable. Keep away from heat or fire.

See Important Safety Information. See Full Prescribing Information.

Sofdra
(sofopirium bromide) gel

Sofdra is a retrometabolically designed drug—the first new molecular entity ever approved for primary axillary hyperhidrosis

Sofdra
(sofopirium bromide) gel

Botanix's novel retrometabolically-designed formulation is delivered by a proprietary applicator to keep the drug off patients' hands

- No added fragrance
- No aluminum

Apply 1 pump of Sofdra per underarm once a day at bedtime

Sofdra is supplied in a multi-dose metered pump, applicator, and cap. Each bottle is capable of dispensing 60 pump applications in 30-day supply.

How to Apply Sofdra
Apply once per day at bedtime. See Important Safety Information for more information.

Important Safety Information
Sofdra is flammable. Keep away from heat or fire.

See Important Safety Information. See Full Prescribing Information.

Sofdra
(sofopirium bromide) gel

Effective first-line topical treatment for primary axillary hyperhidrosis in patients 9 years of age and older.

Highly statistically significant off-caps outcomes in subjects with primary axillary hyperhidrosis

Go Primary Efficacy Endpoints (Pooled Data)

| Endpoint | Percentage |
|---|------------|
| ≥2 point improvement in HD5M-Ax-7 from Baseline to EOT | 60% |
| ≥1 point improvement in HD5M-Ax-7 from Baseline to EOT | 75% |
| ≥1 point improvement in HD5M-Ax-7 from Baseline to EOT (with cap) | 75% |
| ≥1 point improvement in HD5M-Ax-7 from Baseline to EOT (with cap) | 75% |

or breastfeeding women or pediatric patients under 9 years of age.

See Important Safety Information. See Full Prescribing Information.

Sofdra
(sofopirium bromide) gel

Sofdra
(sofopirium bromide) gel

If you're drier and you show it, raise your hand.

Sara Sofdra patient
"That's me, confident in light gray and looking drier"

Sofdra
(sofopirium bromide) gel

ersonal use only

HOME | **HOW TO USE** | **EFFICACY** | **SAFETY**

Sofdra.
(sopironium bromide) gel

Significant sweat reduction for the majority of patients. That's a Total SOFDRA Move.

Calculated GSP values at EOT for primary endpoint and selected secondary endpoint compared to controls in 11.68 hours.*

*Baseline GSP mg/5 min multiplied by 12 equals mg sweat per hour (211*12=2532 mg/hour). Time to sweat one ounce is mg per ounce divided by mg sweat per hour (29,573.5295625/2532=11.68 per hour) if sweating rate was constant. Dividing EOT (72.9/63.27) mg by Baseline (211) mg produced percentages (34.55%/29.99%) that were applied to one ounce for each EOT measure shown.

STUDY DESIGN

One Ounce
An average subject could fill this test tube

BASELINE
An average subject could fill this test tube

3 out of 5 (60%) patients using SOFDRA achieved near normal sweat levels at 6 weeks

Normal Controls

~1 out of 3 (32%) patients using SOFDRA achieved ≥70% reduction in sweat levels at 6 weeks

INDICATION
Lorem ipsum dolor sit amet, consectetur adipiscing elit, nonummy nibh euismod ut laoreet dolore magna erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore euismod ut nulla facilisis at vero eros et accumsan et iusto odio dignissim qui blandit praesent lacinia mauris tincidunt augue interdum velit euismod a nulla facilisi.

IMPORTANT SAFETY INFORMATION
Lorem ipsum dolor sit amet, consectetur adipiscing elit, nonummy nibh euismod ut laoreet dolore magna erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore euismod ut nulla facilisis at vero eros et accumsan et iusto odio dignissim qui blandit praesent lacinia mauris tincidunt augue interdum velit euismod a nulla facilisi.

FULL IMPORTANT INFORMATION

REFERENCES

Bringing our data to life

 **Sofdra**[™]
(sofipronium bromide) gel, 15%

 **botanix**
PHARMACEUTICALS


COMMERCIAL
DAY
2024

Sales force and market opportunity

ersonal use only

Target most productive prescribers and expand reach via digital channels

- ❖ Identify doctors with greatest potential for prescribing and reimbursement
- ❖ Expand doctor reach using search, media, PR, social, influencers, key opinion leaders
- ❖ Rapid scale-up of a 20-30 field sale reps to call on targeted high potential doctors



Sofpironium Bromide performance in Japan supports *Sofdra* commercial success



Mitigation of Commercial & Clinical Risk

- ❖ ~ 350,000 units of Ecclock sold by Kaken in the last 12 months
- ❖ The incidence and prevalence of hyperhidrosis in Japan and the USA is similar
- ❖ The population of Japan is ~ 1/3rd the size of the USA
- ❖ Kaken has been able to mobilize significant numbers of new patients even in the third year of launch

| | |
|---------------|---|
| Approval Date | September 25, 2020, in Japan |
| Indication | Primary axillary hyperhidrosis |
| Launch Date | November 26, 2020 |
| Application | An applicator allows for drug application without the need for the patient to touch the product |
| Name | Ecclock® |

Source: Kaken Company Website, Kaken Press Release November 18, 2020, Kaken 2021 Corporate Report, FreshTracks Pharma (FKA Brickell Bio) Press Release June 24, 2021.

 **Sofdra**[™]
(sofipronium bromide) gel, 15%


botanix
PHARMACEUTICALS

COMMERCIAL
DAY
2024

In Summary

ersonal use only



Botanix is rapidly preparing to launch *Sofdra* gel

Scale & Prepare the Organization

- Executive team
- Infrastructure
- Office staffing
- Field force
- Data warehouse

Product Availability

- Contract manufacturer
- Serialization vendor
- DP scale pre-validation
- DP quality agreements
- State licensing vendor
- 3PL vendor
- Final packaging & labeling

Product Access

- Payer strategy
- Managed care vendor
- Payer engagement
- Pricing established
- Telehealth vendor
- Central pharmacy

Medical & Regulatory

- MIS/AE vendor
- Human factors study
- PDUFA June 20, 2024

Sales & Marketing

- Ad Agency
- Brand positioning
- Core messaging
- HCP strategy
- Consumer strategy
- Sales force alignment
- Launch materials